Clinical Trials Sponsored by Meta Pharm Development, LLC

Total 28 results

SCRI Development Innovations, LLC
Acerta Pharma, LLC

Completed

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

Solid Tumors

United States
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Terminated

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Solid Tumors

United States, United Kingdom
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Solid Tumors

United States
MENA Center for Research & Development and Internship
Merck Sharp & Dohme LLC

Recruiting

The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan (RSV-JO)

Respiratory Syncytial Virus Infections

Jordan
Pharm-Olam, LLC
Biomedical Advanced Research and Development Authority

Terminated

Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents (CoVacSpec)

COVID-19

United States, South Africa, Colombia, Guadeloupe, India, Mexico, Puerto Rico
Astellas Pharma Global Development, Inc.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Healthy Subjects | Pharmacokinetics of Fidaxomicin

United States
SCRI Development Innovations, LLC
Roche Pharma AG; Sanofi-Synthelabo

Completed

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Neoplasms, Unknown Primary

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Portugal, Spain, United Kingdom, Italy, Canada, Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of ASP1570 Taken by Itself or With Pembrolizumab in Adults With Solid Tumors

Advanced Solid Tumors

United States, Japan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors

Metastatic Cancer | Advanced Cancer | Solid Tumors

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Canada, Taiwan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Canada, Italy, Japan, Portugal, Spain, United Kingdom
4D pharma plc
ICON plc; Labcorp Drug Development Inc

Withdrawn

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Idiopathic Parkinson Disease
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Active, not recruiting

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Italy, Spain, Canada, France, Puerto Rico
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Urothelial Cancer

United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
Merck Sharp & Dohme LLC
Seagen Inc.; Astellas Pharma Global Development, Inc.

Recruiting

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Sweden, Thailand, T... and more
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)

United States, Belgium, Canada, Italy, Spain, United Kingdom
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)

Prostate Cancer

United States, Canada
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Metastatic Castration-Resistant Prostate Cancer

United States
MEDA Pharma GmbH & Co. KG
ICON plc; Clinipace Worldwide; Trium Analysis Online GmbH

Terminated

Tepilta® Versus Oxetacaine, Antacids and Placebo

Radiation-induced Oesophagitis

Germany, Austria
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH; Trio Clinical Research, LLC, Raleigh, USA; NuCara Pharmacy... and other collaborators

Completed

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Asthma

United States
N-Gene Research Laboratories, Inc.
Thermo Fisher Scientific, Inc; Integrium; Msource Medical Development GmbH; Kinexum... and other collaborators

Terminated

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Germany, Hungary
AIO-Studien-gGmbH
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaborators

Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)

Small-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

Germany
US Department of Veterans Affairs
Bristol-Myers Squibb; Sanofi; GE Healthcare; Merck Sharp & Dohme LLC; Pfizer; Astra... and other collaborators

Completed

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Myocardial Ischemia

United States, Canada

Clinical Trials Sponsored by Meta Pharm Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations